4.6 Article

Identification of treatment goals in paediatric pulmonary arterial hypertension

期刊

EUROPEAN RESPIRATORY JOURNAL
卷 44, 期 6, 页码 1616-1626

出版社

EUROPEAN RESPIRATORY SOC JOURNALS LTD
DOI: 10.1183/09031936.00030414

关键词

-

向作者/读者索取更多资源

To be able to design goal-oriented treatment strategies in paediatric pulmonary arterial hypertension (PAH), we aimed to identify treatment goals by investigating the prognostic value of treatment-induced changes in noninvasive predictors of transplant-free survival. 66 consecutive, treatment-naive paediatric PAR patients in the Dutch National Network for Paediatric Pulmonary Hypertension who started taking PAR-targeted drugs between January 2000 and April 2013 underwent prospective, standardised follow-up. Clinical, biochemical and echocardiographic measures were longitudinally collected at treatment initiation and follow-up, and their respective predictive values for transplant-free survival were assessed. Furthermore, the predictive values of treatment-induced changes were assessed. From the identified set of baseline predictors, the variables World Health Organization functional class (WHO-PC), N-terminal pro-brain natriuretic peptide (NT-proBNP) and tricuspid annular plane systolic excursion (TAPSE) were identified as follow-up predictors in which treatment-induced changes were associated with survival. Patients in whom these variables improved after treatment showed better survival (p<0.002). Therefore, WHO-FC, NT-proBNP and TAPSE are not only predictors of transplant-free survival in paediatric PAR but can also be used as treatment goals, as treatment-induced improvements in these variables are associated with improved survival. The identification of these variables allows for the introduction of goal-oriented treatment strategies in paediatric PAR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Letter Critical Care Medicine

Impaired Right Ventricular-Vascular Coupling in Young Adults Born Preterm

Ashley Mulchrone, Alessandro Bellofiore, Johannes M. Douwes, Neal Duong, Arij G. Beshish, Gregory P. Barton, Christopher J. Francois, Marlowe W. Eldridge, Kara N. Goss, Naomi C. Chesler

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2020)

Review Cardiac & Cardiovascular Systems

Metabolic Remodeling in the Pressure-Loaded Right Ventricle: Shifts in Glucose and Fatty Acid Metabolism-A Systematic Review and Meta-Analysis

Anne-Marie C. Koop, Guido P. L. Bossers, Mark-Jan Ploegstra, Quint A. J. Hagdorn, Rolf M. F. Berger, Herman H. W. Sillje, Beatrijs Bartelds

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2019)

Article Cardiac & Cardiovascular Systems

Novel measures of left ventricular electromechanical discoordination predict clinical outcomes in children with pulmonary arterial hypertension

Benjamin S. Frank, Michal Schafer, Johannes M. Douwes, D. Dunbar Ivy, Steven H. Abman, Jesse A. Davidson, Sandra Burzlaff, Max B. Mitchell, Gareth J. Morgan, Lorna P. Browne, Alex J. Barker, Uyen Truong, Johannes C. von Alvensleben

AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2020)

Article Pediatrics

Serial Measurements of N-Terminal Pro-B-Type Natriuretic Peptide Serum Level for Monitoring Pulmonary Arterial Hypertension in Children

Fatema Said, Meindina G. Haarman, Marcus T. R. Roofthooft, Hans L. Hillege, Mark-Jan Ploegstra, Rolf M. F. Berger

JOURNAL OF PEDIATRICS (2020)

Article Cardiac & Cardiovascular Systems

N-terminal pro-brain natriuretic peptide serum levels reflect attrition of the Fontan circulation

Djoeke Wolff, Joost P. van Melle, Tineke P. Willems, Beatrijs Bartelds, Mark-Jan Ploegstra, Hans Hillege, Tjark Ebels, Rolf M. F. Berger

CARDIOLOGY IN THE YOUNG (2020)

Article Respiratory System

Upfront triple combination therapy in severe paediatric pulmonary arterial hypertension

Meindina G. Haarman, Marilyne Levy, Marcus T. R. Roofthooft, Johannes M. Douwes, Theresia R. Vissia-Kazemier, Isabelle Szezepanski, Rolf M. F. Berger, Damien Bonnet

Summary: This retrospective observational study evaluated the efficacy of upfront triple combination therapy (uTCT) in paediatric PAH, showing that children with idiopathic and heritable PAH had high transplant-free survival rates up to 3 years, despite a significant proportion receiving a Potts shunt during follow-up. The findings suggest that uTCT may be beneficial for children with severe PAH, but further research is needed to determine the role of a Potts shunt in conjunction with uTCT in paediatric PAH.

EUROPEAN RESPIRATORY JOURNAL (2021)

Review Cardiac & Cardiovascular Systems

Prognostic biomarkers in pediatric pulmonary arterial hypertension

Mark-Jan Ploegstra, Rolf M. F. Berger

Summary: Children with pulmonary arterial hypertension (PAH) require reliable prognostic biomarkers to guide their treatment decisions, and there are many types of potential prognostic biomarkers available for the management of PAH. A multi-marker approach may be the most effective in guiding treatment decisions and improving outcomes.

CARDIOVASCULAR DIAGNOSIS AND THERAPY (2021)

Review Cardiac & Cardiovascular Systems

Risk stratification in adult and pediatric pulmonary arterial hypertension: A systematic review

Chantal Lokhorst, Sjoukje van der Werf, Rolf M. F. Berger, Johannes M. M. Douwes

Summary: This systematic review examines the variables and prognostic value of risk stratification models in adult and pediatric pulmonary arterial hypertension. The study finds that the most commonly used variables in current risk stratification models are WHO functional class, 6-minute walk distance, and BNP/NT-proBNP. The c-statistics of risk stratification models range from 0.56 to 0.83 in adults and 0.69 to 0.78 in children.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2022)

Article Pediatrics

Cardiac Magnetic Resonance Derived Left Ventricular Eccentricity Index and Right Ventricular Mass Measurements Predict Outcome in Children with Pulmonary Arterial Hypertension

Meindina G. G. Haarman, Iris Coenraad, Quint A. J. Hagdorn, Hans L. L. Hillege, Tineke P. P. Willems, Rolf M. F. Berger, Johannes M. M. Douwes

Summary: Cardiac magnetic resonance (CMR)-derived measures of right ventricular (RV) morphology and function can predict the outcome of children with pulmonary arterial hypertension (PAH), which is crucial for treatment strategies.

CHILDREN-BASEL (2023)

Article Cardiac & Cardiovascular Systems

Long-term outcome of children with newly diagnosed pulmonary arterial hypertension: results from the global TOPP registry

Mark-Jan Ploegstra, David Dunbar Ivy, Maurice Beghetti, Damien Bonnet, Dursun Alehan, Laszlo Ablonczy, Sandra Mattos, David Bowers, Tilman Humpl, Rolf M. F. Berger

Summary: The study describes the long-term outcomes and predictors for newly diagnosed pediatric patients with pulmonary arterial hypertension (PAH). The results showed that among the 242 patients who underwent long-term follow-up, 17.4% died, 3.7% underwent lung transplantation, 1.2% underwent atrial septostomy, and 3.7% underwent Potts shunt palliation. Younger age, worse World Health Organization functional class, and higher pulmonary vascular resistance index were identified as independent predictors of long-term adverse outcome.

EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES (2023)

Article Cardiac & Cardiovascular Systems

Pirfenidone ameliorates pulmonary arterial pressure and neointimal remodeling in experimental pulmonary arterial hypertension by suppressing NLRP3 inflammasome activation

Emmanouil Mavrogiannis, Quint A. J. Hagdorn, Venetia Bazioti, Johannes M. Douwes, Diederik E. van der Feen, Silke U. Oberdorf-Maass, Marit Westerterp, Rolf M. F. Berger

Summary: Pulmonary arterial hypertension (PAH) is a fatal disease characterized by increased pulmonary arterial pressure, inflammation, and neointimal remodeling of pulmonary arterioles. Serum levels of interleukin (IL)-1 beta and IL-18 are elevated in PAH patients and may enhance proinflammatory neointimal remodeling. Pirfenidone (PFD), an antifibrotic and anti-inflammatory drug, has been suggested to inhibit NLRP3 inflammasome activation, delaying the progression of PAH.

PULMONARY CIRCULATION (2022)

Article Respiratory System

Parenteral Prostanoids in Pediatric Pulmonary Arterial Hypertension Start Early, Dose High, Combine

Johannes M. Douwes, Willemijn M. H. Zijlstra, Erika B. Rosenzweig, Mark-Jan Ploegstra, Usha S. Krishnan, Meindina G. Haarman, Marcus T. R. Roofthooft, Douwe Postmus, Hans L. Hillege, D. Dunbar Ivy, Rolf M. F. Berger

Summary: This study retrospectively analyzed data from 275 children with PAH and found that early initiation and higher doses of IV/SC prostanoid therapy, as well as combination with other targeted drugs, were associated with better outcomes. Transition from IV/SC prostanoid therapy to oral or inhaled therapies was found to be safe in selected patients who met specific hemodynamic criteria.

ANNALS OF THE AMERICAN THORACIC SOCIETY (2022)

Article Respiratory System

Pulmonary arterial hypertension associated with pulmonary arteriovenous malformations and pulmonary veno-occlusive disease: A devastating combination

Baukje M. Zaaijer, Nienke Duppen, Brigitte W. M. Willemse, Martijn V. Verhagen, Marcus T. R. Roofthooft, Wim Timens, Rolf M. F. Berger, Johannes M. Douwes

Summary: This case illustrates the diversity of diseases causing PAH and underscores the importance of questioning the original diagnosis when there is an unexpected treatment response. The presence of PAH and PAVM's in the patient does not necessarily indicate a confirmed link to HHT.

RESPIRATORY MEDICINE CASE REPORTS (2021)

Article Cardiac & Cardiovascular Systems

Ventricular-vascular coupling is predictive of adverse clinical outcome in paediatric pulmonary arterial hypertension

Melanie J. Dufva, Dunbar Ivy, Kristen Campbell, Aimee Lam, Adam Rauff, Karel T. N. Breeman, Johannes M. Douwes, Rolf M. F. Berger, Vitaly Oleg Kheyfets, Kendall Hunter

Summary: The ventricular-vascular coupling ratio (E-es/E-a) derived from pressure alone is a strong independent predictor of adverse outcome in pediatric pulmonary arterial hypertension (PAH), serving as a potentially powerful prognostic tool.

OPEN HEART (2021)

暂无数据